论文部分内容阅读
将大脑胶质瘤在组织学分类和临床病理上分出Ⅱ级和Ⅲ级,这对WHO而言是一个重大的挑战。本文作者设想利用大规模基因组和转录组学分析是否能分出更为明确的不同预后类型。作者基于微阵列的基因组和转录组方法分析了137例原发大脑胶质瘤,病例来自一个前瞻性的德国胶质瘤网(German Glioma Network),其中包括61例WHO II级和76例WHO III级的肿瘤患者。用综合生物信息学分析确定分子亚型,然后将其与组织学、分子生物标记和患者预后相
It is a major challenge for WHO to classify glioma in histological classification and clinicopathological grade Ⅱ and Ⅲ. The authors envisage using large-scale genomic and transcriptomic analyzes to identify more distinct types of prognosis. The authors analyzed 137 primary brain gliomas based on microarray-based genomic and transcriptomic methods from a prospective German Glioma Network, including 61 WHO class II and 76 WHO III Tumor patients. Using molecular bioinformatics analysis to determine molecular subtypes, and then with histology, molecular biomarkers and prognosis